JP7536243B2 - Ｍａｐキナーゼ相互作用セリン／スレオニン－プロテインキナーゼ１（ｍｎｋ１）及びｍａｐキナーゼ相互作用セリン／スレオニン－プロテインキナーゼ２（ｍｎｋ２）の阻害剤、癌治療及び治療的組合せ - Google Patents

Ｍａｐキナーゼ相互作用セリン／スレオニン－プロテインキナーゼ１（ｍｎｋ１）及びｍａｐキナーゼ相互作用セリン／スレオニン－プロテインキナーゼ２（ｍｎｋ２）の阻害剤、癌治療及び治療的組合せ Download PDF

Info

Publication number
JP7536243B2
JP7536243B2 JP2022500764A JP2022500764A JP7536243B2 JP 7536243 B2 JP7536243 B2 JP 7536243B2 JP 2022500764 A JP2022500764 A JP 2022500764A JP 2022500764 A JP2022500764 A JP 2022500764A JP 7536243 B2 JP7536243 B2 JP 7536243B2
Authority
JP
Japan
Prior art keywords
cancer
pharma
doxorubicin
treatment
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022500764A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021005183A5 (https=
JP2022539840A5 (https=
JP2022539840A (ja
Inventor
イ カハール アグエラス，サンティアゴ ラモン
ウメル，ステファン
ビベス，ジョセップ カステリャビ
サエス，エレナ マルチネス
ビルバオ，ホセ イグナシオ ボレル
クローサ，ジョルディ テイシード
テヘドル，ロジャー エストラーダ
プティ，エリザベス ボウ
カマラ，ビセンテ ペグ
カリージョ，ペドロ ヘスス キハロ
マルガレフ，アンナ サンタマリア
ロブレス，ジョアン モロテ
カブレラ，レティシア スアレス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Investigacion Biomedica en Red CIBER
Original Assignee
Centro de Investigacion Biomedica en Red CIBER
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro de Investigacion Biomedica en Red CIBER filed Critical Centro de Investigacion Biomedica en Red CIBER
Publication of JP2022539840A publication Critical patent/JP2022539840A/ja
Publication of JPWO2021005183A5 publication Critical patent/JPWO2021005183A5/ja
Publication of JP2022539840A5 publication Critical patent/JP2022539840A5/ja
Application granted granted Critical
Publication of JP7536243B2 publication Critical patent/JP7536243B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022500764A 2019-07-10 2020-07-09 Ｍａｐキナーゼ相互作用セリン／スレオニン－プロテインキナーゼ１（ｍｎｋ１）及びｍａｐキナーゼ相互作用セリン／スレオニン－プロテインキナーゼ２（ｍｎｋ２）の阻害剤、癌治療及び治療的組合せ Active JP7536243B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES201930643 2019-07-10
ESP201930643 2019-07-10
PCT/EP2020/069459 WO2021005183A1 (en) 2019-07-10 2020-07-09 Inhibitor of map kinase interacting serine/threonine kinase 1 (mnk1) and map kinase interacting serine/threonine kinase 2 (mnk2), cancer therapy and therapeutic combinations

Publications (4)

Publication Number Publication Date
JP2022539840A JP2022539840A (ja) 2022-09-13
JPWO2021005183A5 JPWO2021005183A5 (https=) 2023-07-18
JP2022539840A5 JP2022539840A5 (https=) 2023-07-18
JP7536243B2 true JP7536243B2 (ja) 2024-08-20

Family

ID=71607975

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022500764A Active JP7536243B2 (ja) 2019-07-10 2020-07-09 Ｍａｐキナーゼ相互作用セリン／スレオニン－プロテインキナーゼ１（ｍｎｋ１）及びｍａｐキナーゼ相互作用セリン／スレオニン－プロテインキナーゼ２（ｍｎｋ２）の阻害剤、癌治療及び治療的組合せ

Country Status (5)

Country Link
US (1) US20220257571A1 (https=)
EP (1) EP3996710B1 (https=)
JP (1) JP7536243B2 (https=)
ES (1) ES3014017T3 (https=)
WO (1) WO2021005183A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11958832B1 (en) 2023-10-12 2024-04-16 King Faisal University 2-alkoxy[4,3:6,3-terpyridine]-3-carbonitriles as antimicrobial compounds
US11926611B1 (en) 2023-11-24 2024-03-12 King Faisal University 2-(2-ethoxyethoxy)-6-phenyl-4,4′-bipyridine-3-carbonitrile as an antimicrobial compound
US12071407B1 (en) 2023-12-05 2024-08-27 King Faisal University 6-(4-hydroxyphenyl)-2-(2-ethoxyethoxy)-4-(4-methoxyphenyl)nicotinonitrile as an antimicrobial compound
US11970451B1 (en) 2023-12-07 2024-04-30 King Faisal University 6-(3-hydroxyphenyl)-2-methoxy-4-(3-methylphenyl)nicotinonitrile as an antimicrobial compound

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2160780A1 (de) 1971-12-08 1973-06-14 Basf Ag Pyridino-pyrazole
EP2464647B1 (en) 2009-08-11 2016-09-21 Bristol-Myers Squibb Company Azaindazoles as btk kinase modulators and use thereof
AU2014289415A1 (en) 2013-07-08 2016-01-21 Bayer Pharma Aktiengesellschaft Substituted pyrazolo-pyridinamines
US10702526B2 (en) * 2015-04-20 2020-07-07 Effector Therapeutics Inc. Inhibitors of immune checkpoint modulators and related methods

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Current Oncology Reports，2018年，Vol.20，Article No.94
Current Opinion in Pharmacology，2015年，Vol.23，p.32-38
Molecules，2016年，Vol.21，Article No.30

Also Published As

Publication number Publication date
WO2021005183A1 (en) 2021-01-14
EP3996710A1 (en) 2022-05-18
EP3996710B1 (en) 2025-01-22
JP2022539840A (ja) 2022-09-13
EP3996710C0 (en) 2025-01-22
ES3014017T3 (en) 2025-04-16
US20220257571A1 (en) 2022-08-18

Similar Documents

Publication Publication Date Title
JP7536243B2 (ja) Ｍａｐキナーゼ相互作用セリン／スレオニン－プロテインキナーゼ１（ｍｎｋ１）及びｍａｐキナーゼ相互作用セリン／スレオニン－プロテインキナーゼ２（ｍｎｋ２）の阻害剤、癌治療及び治療的組合せ
Pontes et al. Renal cell carcinoma therapy: current and new drug candidates
US7566716B2 (en) Imidazopyrazines as Raf inhibitor compounds
EP2960234B1 (en) Trk-inhibiting compound
Lei et al. Inhibition of MGMT-mediated autophagy suppression decreases cisplatin chemosensitivity in gastric cancer
Cao et al. Cap-dependent translation initiation factor, eIF4E, is the target for Ouabain-mediated inhibition of HIF-1α
AU2018200323A1 (en) Combination therapy
CN106488767A (zh) 调节雌激素受体突变体的方法和组合物
Song et al. Discovery and characterization of novel imidazopyridine derivative CHEQ-2 as a potent CDC25 inhibitor and promising anticancer drug candidate
Ku et al. Transglutaminase 2 inhibitor abrogates renal cell carcinoma in xenograft models
Yeh et al. Flavopereirine induces cell cycle arrest and apoptosis via the AKT/p38 MAPK/ERK1/2 signaling pathway in human breast cancer cells
WO2015184983A1 (zh) 一种雷帕霉素衍生物、其制备方法、其药物组合物及用途
Xu et al. Discovery of novel polycyclic heterocyclic derivatives from evodiamine for the potential treatment of triple-negative breast cancer
CN109982701A (zh) SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途
WO2016109470A1 (en) Small molecule stimulators of steroid receptor coactivator proteins and their use in the treatment of cancer
Li et al. Isoliensinine induces cervical cancer cell cycle arrest and apoptosis by inhibiting the AKT/GSK3α pathway
Li et al. Development of a novel thymidylate synthase (TS) inhibitor capable of up-regulating P53 expression and inhibiting angiogenesis in NSCLC
Carpenter et al. Efficacy and safety of sonic hedgehog pathway inhibitors in cancer
TWI863667B (zh) 用於治療疾病之磷酸肌醇3-激酶(pi3k)異位色烯酮抑制劑
WO2021207352A1 (en) Compositions and methods for treatment of anticancer-drug resistant cancers
Ramón y Cajal Agüeras et al. Inhibitor of map kinase interacting serine/threonine kinase 1 (mnk1) and map kinase interacting serine/threonine kinase 2 (mnk2), cancer therapy and therapeutic combinations
KR20210060642A (ko) 성장 관련 질환 및/또는 그것의 임상적 상태를 억제 및/또는 치료하기 위한 조성물 및 방법
KR101207981B1 (ko) 호르몬 불응성 전립선암의 예방 또는 치료용 약제학적 조성물 및 그의 스크리닝 방법
Tan et al. A novel 20 (R) dammarane panaxadiol-indole-2', 3'-dione derivative was found to inhibit the growth and migration of colorectal cancer cells by inhibiting EGFR-mediated RalA/EMT pathway
Gao et al. A novel amino-pyrimidine inhibitor suppresses tumor growth via microtubule destabilization and Bmi-1 down-regulation

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230707

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230928

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240702

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240726

R150 Certificate of patent or registration of utility model

Ref document number: 7536243

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150